ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 4, 2012, Pages 902-909

  Siller Matula, Jolanta M ^a   Merhi, Yahye ^b   Tanguay, Jean François ^b   Duerschmied, Daniel ^c,d,e   Wagner, Denisa D ^c,d,f   McGinness, Kathleen E ^g   Pendergrast, P Shannon ^g   Chung, Jou Ku ^g   Tian, Xianbin ^g   Schaub, Robert G ^g   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MONTREAL HEART INSTITUTE   (Canada)

^c CENTER FOR BLOOD RESEARCH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g Archemix Corporation   (United States)

Author keywords

adhesion molecules; antiplatelet drugs; arterial thrombosis; coagulation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; APTAMER; ARACHIDONIC ACID; ARC 15105; ARC 1709; BLOOD CLOTTING INHIBITOR; CLOPIDOGREL; HEPARIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AGED; ANIMAL TISSUE; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG STABILITY; EXPERIMENTAL MONKEY; HUMAN; HUMAN CELL; IC 50; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION;

AGED; ANIMALS; APTAMERS, NUCLEOTIDE; APTAMERS, PEPTIDE; AUSTRIA; BIOLOGICAL AVAILABILITY; BLOOD PLATELETS; BOSTON; CASE-CONTROL STUDIES; COLLAGEN; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MACACA FASCICULARIS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROTEIN BINDING; QUEBEC; RATS; SWINE; VON WILLEBRAND FACTOR;

EID: 84858690837     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.237529     Document Type: Article

References (27)

1. Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost. 2008;99:264-270. (Pubitemid 351230954)
2. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117: 1449-1459. (Pubitemid 351501497)
3. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424. (Pubitemid 28411134)
4. Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem. 1991;266:21948-21955. (Pubitemid 121000273)
5. Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, Choussat R, Beygui F, Borentain M, Vignolles N, Thomas D. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003;108:391-394. (Pubitemid 36935529)
6. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost. 2006;4:2547-2552. (Pubitemid 44741545)
7. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635-641.
8. Siller-Matula J, Schror K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost. 2007; 97:385-393. (Pubitemid 46437800)
9. Firbas C, Siller-Matula JM, Jilma B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther. 2010;8: 1689-1701.
10. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disease. British Journal of Pharmacology. 2009;159:502-517.
11. Spiel AO, Mayr FB, Ladani N, Wagner PG, Schaub RG, Gilbert JC, Jilma B. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets. 2009;20:334-340.
12. Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knobl P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost. 2010;104:563-570.
13. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knobl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;105:545-552.
14. Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knöbl P, Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;106:539-547.
15. Gutsaeva DR, Parkerson JB, Yerigenahally SD, Kurz JC, Schaub RG, Ikuta T, Head CA. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood. 2011;117: 727-735.
16. Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple Electrode Aggregometry predicts stent thrombosis better than the VASP assay. J Thromb Haemost. 2010;8:351-359.
17. Siller-Matula JM, Gouya G, Wolzt M, Jilma B. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost. 2009;102:397-403.
18. Siller-Matula JM, Haberl K, Prillinger K, Panzer S, Lang I, Jilma B. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res. 2009;123:874-880.
19. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med. 2001;138:152-163. (Pubitemid 32812228)
20. Derhaschnig U, Pachinger C, Jilma B. Variable inhibition of high-shearinduced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial. Am Heart J. 2004;147:E17.
21. Arzamendi D, Dandachli F, Theoret JF, Ducrocq G, Chan M, Mourad W, Gilbert JG, Schaub RG, Tanguay JF, Merhi Y. An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis. Clin Appl Thromb Hemost. 2010:doi:10.1177/1076029610384114.
22. Diener JL, Daniel Lagasse HA, Duerschmied D, Merhi Y, Tanguay JF, Hutabarat R, Gilbert J, Wagner DD, Schaub R. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost. 2009;7:1155-1162.
23. Theoret JF, Bienvenu JG, Kumar A, Merhi Y. P-selectin antagonism with recombinant p-selectin glycoprotein ligand-1 (rPSGL-Ig) inhibits circulating activated platelet binding to neutrophils induced by damaged arterial surfaces. J Pharmacol Exp Ther. 2001;298:658-664. (Pubitemid 32673417)
24. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res. 2007;100:1673-1685. (Pubitemid 46987859)
25. Mayr FB, Knobl P, Jilma B, Siller-Matula JM, Wagner PG, Schaub RG, Gilbert JC, Jilma-Stohlawetz P. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion. 2010;50:1079-1087.
26. Becker RC, Povsic T, Cohen MG, Rusconi CP, Sullenger B. Nucleic acid aptamers as antithrombotic agents: opportunities in extracellular therapeutics. Thromb Haemost. 2010;103:586-595.
27. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG. Firstin-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007;116:2678-2686. (Pubitemid 350291240)